<p>Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.</p>

Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma.

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

Share What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

Sign up to save your podcasts

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

More shows like Hematologic Oncology Update

JAMA Editors' Summary

Gastrointestinal Cancer Update

Lung Cancer Update

Prostate Cancer Update

Breast Cancer Update

Gynecologic Oncology Update

Dermatologic Oncology Update

NEJM This Week

Research To Practice | Oncology Videos

The Hematologist

JAMA Clinical Reviews

Annals On Call Podcast

Blood Podcast

Oncology Today with Dr Neil Love

WolverHeme Happy Hour

Two Onc Docs

Blood Cancer Talks